Login / Signup

Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.

Joshua F Zeidner
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Isocitrate dehydrogenase (IDH) inhibitors have clinical activity in acute myeloid leukemia, in part, by differentiating blasts to mature myeloid cells. In the largest systematic analysis to date, differentiation syndrome was seen in 19% of patients treated with IDH inhibitors. Early recognition with uniform diagnostic criteria, as utilized in acute promyelocytic leukemia, may reduce subsequent complications.See related article by Norsworthy et al., p. 4280.
Keyphrases